The global cardiac marker testing market was valued at USD 3.9 billion in 2021 and it is anticipated to grow at 10.4% CAGR during the forecast period to reach up to USD 10.5 billion by 2031.
New York, Global Cardiac Marker Testing Market report from Global Insight Services is the single authoritative source of intelligence on Cardiac Marker Testing Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters’ and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.
Get Access to A Free Sample Copy of Our Latest Report – https://www.globalinsightservices.com/request-sample/GIS10254/
Cardiac markers are utilized in the treatment and risk stratification of patients with the suspected coronary acute syndrome (ACS). Troponin I and T, HDCRP, myoglobin, CK-MB, and other cardiac marker tests are among the most common. When the heart is stressed or injured, substances called cardiac markers are released into the blood. Hormones, enzymes, and proteins are examples of these markers.
- Roche Diagnostics Ltd. (Switzerland)
- Abbott Laboratories (US)
- Siemens Healthineers AG (Germany)
- Danaher Corporation (US)
- bioMérieux SA (France)
- LSI Medience Corporation (Japan)
- Ortho Clinical Diagnostics (US)
- Randox laboratories Ltd. (UK)
Market Trends and Drivers
The key factor boosting the growth of the market is the growing incidence of cardiovascular diseases. The prevalence of lifestyle diseases such as hypertension, obesity, dyslipidemia, and diabetes, which are major risk factors for CVD, is also on the rise. In 2016, more than 1.9 billion adults globally were overweight; of these, over 600 million people were obese. It is anticipated that ~41% of the world’s population will be overweight or obese by 2030. The association between obesity and the risk of coronary heart disease was published by investigators (Bogers RP, Bemelmans WJ, Hogeveen RT, et al.) by a meta-analysis of 21 long-term studies conducted by them with more than 300,000 participants. It was witnessed that participants who were overweight had a 32% higher risk of developing coronary artery disease (CAD), and those who were obese had an 81% higher risk as compared with participants who were a normal weight.
Free Customization Available – https://www.globalinsightservices.com/request-customization/GIS10254
- Reagents & Kits
By Biomarker Type
- Troponin I and T
- Bnp or Nt-Probnp
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
By End User
- Laboratory Testing
- Academic Institutes
Purchase This Market Research Report – https://www.globalinsightservices.com/checkout/single_user/GIS10254
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.